Hemin arginate is indicated for hepatic porphyria (intermittent acute porphyria, porphyria variegata and hereditary coproporphyria). Hemin, by contributing to the re-establishment of normal levels of haemoproteins and of respiratory pigments, corrects the biological disorders observed in patients with porphyria.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B06AB | Heme products | B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents |
| B06AB01 | B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AB Heme products | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| NORMOSANG Concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Hemin is an active ingredient of these brands:
Austria (AT)Brazil (BR)Canada (CA)Croatia (HR)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Japan (JP)Lithuania (LT)Malta (MT)Netherlands (NL)Romania (RO)South Africa (ZA)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
